China National Pharmaceutical Group

China National Pharmaceutical Group Corp. (CNPGC) known as Sinopharm is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.).[4] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai) and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).

China National Pharmaceutical Group
Sinopharm
Typestate-owned enterprise
FoundedNovember 26, 1998
Headquarters
Beijing
,
China
Area served
China, exported worldwide
Key people
Guo Jianxin (Chairman & Party Committee Secretary)[1][2]
Revenue CN¥247.110 billion (2014)
CN¥8.758 billion (2014)
CN¥2.705 billion (2014)
Total assets CN¥199.192 billion (2014)
Total equity CN¥31.944 billion (2014)
OwnerChinese central government (100%)
ParentSASAC of the State Council
Subsidiaries
  • Sinopharm Industrial Investment (51%)
  • → Sinopharm Group (56.79%)
  • Trad. Chinese Medicine (37.59%)
  • Shyndec Pharma. (41.62%)
  • China National Biotec Group (95%)
  • → Tiantan Biological (53.30%)
Chinese name
Simplified Chinese中国医药集团总公司
Traditional Chinese中國醫藥集團總公司
short Chinese name
Simplified Chinese国药集团
Traditional Chinese國藥集團
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards[3]

China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[5]

Sinopharm was ranked 205th in 2016 Fortune Global 500 list.[6]

History

China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) was founded on November 26, 1998 as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).

Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.[7]

COVID-19 Vaccine development
Main article: BBIBP-CorV
See also: COVID-19 vaccine § Clinical trials started in 2020

BBIBP-CorV is one of two inactivated virus COVID-19 vaccine being developed by Sinopharm's Beijing and Wuhan subsidiaries. As of December 2020, it is currently in Phase III trials in Argentina,[8] Bahrain,[9] Egypt,[10] Jordan,[11] Morocco,[12] Pakistan,[13] Peru,[14] and United Arab Emirates[15] with over 60,000 people.[16] On December 9, the UAE announced the official registration of BBICP-CorV after an interim analysis of the Phase III trials showed BBIBP-CorV to have a 86% efficacy against COVID-19 infection.[17]

Sinopharm's vaccine has emergency use authorization in Bahrain[18] and UAE.[19] BIBP-CorV could become a favorable option to vaccinate large parts of the developing world. While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of +90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[20]

See also

References
  1. "中国医药集团总公司郭建新职务变动情况" (in Chinese). SASAC of the State Council. 6 May 2014. Retrieved 22 November 2016.
  2. "管理团队" (in Chinese). Sinopharm. Retrieved 22 November 2016.
  3. "中国医药集团总公司2016年度第一期超短期融资券发行披露材料" [Pospectus of 2016 (batch 1) Ultra-short-term financing of Sinopharm]. Sinopharm (in Chinese). Shanghai Clearing House. 19 January 2016. Retrieved 22 November 2016.
  4. "2015 Annual Report" (PDF). China Traditional Chinese Medicine. Hong Kong Stock Exchange. 28 April 2016. Retrieved 22 November 2016.
  5. "央企名录 (List of Central SOEs)". Official website of SASAC (in Chinese). Retrieved 3 March 2016.
  6. http://beta.fortune.com/global500/sinopharm-205
  7. "Chinese President Xi Jinping orders crackdown over 'appalling' vaccine scandal". South China Morning Post. 23 July 2018. Retrieved 29 November 2018.
  8. "Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-12-13.
  9. Barrington, Lisa (2020-11-03). "Bahrain latest country to vaccinate frontline workers with COVID-19 shot". Reuters. Retrieved 2020-12-13.
  10. "Egypt to start receiving volunteers for COVID-19 vaccine trials". Egypt Independent. 2020-09-12. Retrieved 2020-12-13.
  11. "Jordan starts phase 3 trial of China's COVID-19 vaccine". Jordan Times. 2020-08-30. Retrieved 2020-12-13.
  12. "Morocco orders R-Pharm Covid-19 vaccine | The North Africa Post". northafricapost.com. Retrieved 2020-12-28.
  13. "Coronavirus vaccine should be available in Pakistan 'within 6-8 weeks'". www.geo.tv. Retrieved 2020-12-13.
  14. PERÚ, Empresa Peruana de Servicios Editoriales S. A. EDITORA. "Peru: 6,000 additional volunteers required for trials of Sinopharm's COVID-19 vaccine". andina.pe (in Spanish). Retrieved 2020-12-13.
  15. "Coronavirus: 15,000 register as volunteers for Covid-19 vaccine trial in UAE". The National. Retrieved 2020-12-13.
  16. Reuters Staff (2020-11-19). "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. Retrieved 2020-12-09.
  17. "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. Retrieved 2020-12-13.
  18. Barrington, Lisa (3 November 2020). "Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers". Reuters. Retrieved 3 November 2020.
  19. Maxwell, Chris. "Coronavirus: UAE authorises emergency use of vaccine for frontline workers". The National. Retrieved 14 September 2020.
  20. "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 2020-12-09. Retrieved 2020-12-09.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.